MX2012013924A - Cristal de derivado de tienopirimidina. - Google Patents

Cristal de derivado de tienopirimidina.

Info

Publication number
MX2012013924A
MX2012013924A MX2012013924A MX2012013924A MX2012013924A MX 2012013924 A MX2012013924 A MX 2012013924A MX 2012013924 A MX2012013924 A MX 2012013924A MX 2012013924 A MX2012013924 A MX 2012013924A MX 2012013924 A MX2012013924 A MX 2012013924A
Authority
MX
Mexico
Prior art keywords
crystal
thienopyrimidine derivative
crystals
thienopyrimidine
derivative
Prior art date
Application number
MX2012013924A
Other languages
English (en)
Inventor
Hiroyuki Hayashi
Takayoshi Nakagawa
Koichi Miyazaki
Original Assignee
Aska Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharm Co Ltd filed Critical Aska Pharm Co Ltd
Publication of MX2012013924A publication Critical patent/MX2012013924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se obtienen cristales al calentar una suspensión acuosa del ácido 2-(3, 4-diçlorobencil)-5-metil-4-oxo-3, 4-dihidrotieno[2,3-d]pirim idina-6-carboxílico; se obtienen cristales novedosos al ajustar la temperatura de calentamiento y/o su duración.
MX2012013924A 2010-05-31 2011-05-31 Cristal de derivado de tienopirimidina. MX2012013924A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010125362 2010-05-31
PCT/JP2011/062513 WO2011152411A1 (ja) 2010-05-31 2011-05-31 チエノピリミジン誘導体の結晶

Publications (1)

Publication Number Publication Date
MX2012013924A true MX2012013924A (es) 2013-05-01

Family

ID=45066774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013924A MX2012013924A (es) 2010-05-31 2011-05-31 Cristal de derivado de tienopirimidina.

Country Status (15)

Country Link
US (2) US8748437B2 (es)
EP (1) EP2594570B1 (es)
JP (1) JP5744017B2 (es)
KR (1) KR101721288B1 (es)
CN (1) CN103038238B (es)
AU (1) AU2011260861B2 (es)
BR (1) BR112012030689B1 (es)
CA (1) CA2801030C (es)
EA (1) EA021987B1 (es)
ES (1) ES2532110T3 (es)
IL (1) IL223267A (es)
MX (1) MX2012013924A (es)
UA (1) UA111589C2 (es)
WO (1) WO2011152411A1 (es)
ZA (1) ZA201209488B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101721288B1 (ko) 2010-05-31 2017-03-29 아스카 세이야쿠 가부시키가이샤 티에노피리미딘 유도체의 결정
JP2019521192A (ja) 2016-07-07 2019-07-25 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーＣａｒｄｕｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， ＬＬＣ 心不全の処置方法
MX2020010884A (es) * 2018-04-17 2021-02-26 Cardurion Pharmaceuticals Llc Sales de meglumina de tienopirimidinas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4488867B2 (ja) 2004-11-05 2010-06-23 株式会社東芝 パターン形成方法
CN101198614B (zh) * 2005-06-14 2011-07-06 Aska制药株式会社 噻吩并嘧啶衍生物
CA2672591A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Treating agent of uropathy
JP5047136B2 (ja) 2008-11-26 2012-10-10 サンデン株式会社 飲料用容器分別機
KR101721288B1 (ko) * 2010-05-31 2017-03-29 아스카 세이야쿠 가부시키가이샤 티에노피리미딘 유도체의 결정

Also Published As

Publication number Publication date
ZA201209488B (en) 2014-02-26
CN103038238A (zh) 2013-04-10
UA111589C2 (uk) 2016-05-25
ES2532110T3 (es) 2015-03-24
CN103038238B (zh) 2016-05-04
US20130123279A1 (en) 2013-05-16
JPWO2011152411A1 (ja) 2013-08-01
AU2011260861A1 (en) 2013-01-10
US8748437B2 (en) 2014-06-10
EP2594570B1 (en) 2015-02-25
CA2801030C (en) 2018-11-27
KR20130112734A (ko) 2013-10-14
US9006253B2 (en) 2015-04-14
KR101721288B1 (ko) 2017-03-29
BR112012030689B1 (pt) 2021-11-09
AU2011260861B2 (en) 2014-11-13
CA2801030A1 (en) 2011-12-08
EP2594570A4 (en) 2013-11-27
US20140235655A1 (en) 2014-08-21
EP2594570A1 (en) 2013-05-22
BR112012030689A2 (pt) 2016-09-13
IL223267A (en) 2016-10-31
EA201291289A1 (ru) 2013-05-30
WO2011152411A1 (ja) 2011-12-08
EA021987B1 (ru) 2015-10-30
JP5744017B2 (ja) 2015-07-01
IL223267A0 (en) 2013-02-03

Similar Documents

Publication Publication Date Title
IL266285B (en) Methods for the production of thiano [d – 3,2] pyrimidine compounds
IL266897B (en) History of thiano[2,3–d]pyrimidines for the treatment of viral infections
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
HRP20180771T1 (hr) Derivati pirolo[3,2-d]pirimidina za liječenje virusnih infekcija i drugih bolesti
AR083797A1 (es) Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
HK1195309A1 (zh) 作為激酶 調節劑用於治療帕金森病的 -苯基氨基嘧啶衍生物
IL221680A0 (en) Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
MX2013005356A (es) Uso de fluopyram para combatir nematodos en cultivos.
IN2014CN02489A (es)
FR2962731B1 (fr) Procede de preparation de derives d'amino-benzoyl-benzofurane
NZ608031A (en) Inhibitors of notum pectinacetylesterase and methods of their use
MX2013014708A (es) Compuestos que inhiben el glioblastoma y su uso.
AU2012342891A8 (en) 3-Cyanoaryl-1H-pyrrolo[2.3-b]pyridine derivatives
SA518390788B1 (ar) مركب يستهدف إنترلوكين- 23 أ وعامل تنشيط الخلايا البائية واستخداماته
IN2014MN02467A (es)
EP2548949A4 (en) MICROORGANISM WITH IMPROVED PRODUCTION OF 5'-XANTHOSINE MONOPHOSPHATE AND 5'-GUANINE MONOPHOSPHATE AND PRODUCTION PROCESS FOR 5'-XANTHOSINE MONOPHOSPHATE AND 5'-GUANINE MONOPHOSPHATE THEREWITH
MX2012013924A (es) Cristal de derivado de tienopirimidina.
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
MX2016007581A (es) Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos.
MY164134A (en) Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
EP2598485A4 (en) NEW MONTELUKAST 4-HALOGENOBENZYLAMINE SALT AND PROCESS FOR PREPARING MONTELUKAST SODIUM SALT USING THE SAME
HK1203509A1 (en) Improved process for the preparation of 2-substituted-2-(6- (substituted)-7-methylbenzo[d][1,3]dioxol-4-yl)acetic acid derivatives 2--2-(6-)-7-[d][13]-4-)
EP2729475B8 (de) Carbonsäurederivate mit einem oxazolo[5,4-d]pyrimidinring
TH127478B (th) ผลึกของอนุพันธ์ไธเอโนพิริมิดีน
EA201100683A1 (ru) Полиморфные формы 5-этокси-2-[2-(морфолино)этилтио]бензимидазол дигидрохлорида и способы их получения

Legal Events

Date Code Title Description
FG Grant or registration